Taysha Gene Therapies reported a net loss of $46.6 million ($0.13 per share) for the quarter ended June 30, 2026, compared to a $26.9 million loss in the prior year period. Research and development expenses rose to $38.6 million from $20.1 million due to BLA-enabling manufacturing initiatives and higher clinical trial costs. The company completed dosing in its pivotal REVEAL trial (N=17) and ASPIRE trial (N=4) for TSHA-102, a gene therapy for Rett syndrome. Topline data from the REVEAL 6-month interim analysis and FDA feedback are expected in the first half of 2027. Taysha also completed a $230 million follow-on equity offering, bringing cash and cash equivalents to $455.4 million as of June 30, 2026, extending its runway into late 2028. The company operates in the biotechnology industry, developing adeno-associated virus-based gene therapies for severe monogenic diseases of the central nervous system.

Taysha Gene Therapies, Inc. entered into an underwriting agreement with Jefferies LLC and Goldman Sachs & Co. LLC to issue and sell 32,500,001 shares of common stock and 833,333 pre-funded warrants at $6.00 per share and $5.999 per warrant respectively. The company estimates net proceeds of approximately $187.4 million, or $215.6 million if the underwriters exercise their option to purchase an additional 5,000,000 shares. Taysha Gene Therapies, Inc. is a biotechnology company focused on developing gene therapies for neurodevelopmental disorders.

Taysha Gene Therapies, Inc. announced the completion of dosing in the REVEAL Pivotal Trial and reported longer-term clinical data from Part A of the REVEAL Phase 1/2 trials evaluating TSHA-102 for Rett Syndrome. The company provided clinical and regulatory updates on TSHA-102 via a press release and a corporate presentation. Taysha Gene Therapies, Inc. is a biotechnology company focused on developing gene therapies for neurodevelopmental disorders.